The enemy may come individually, or in strength. He may even appear in the form of our own troops.
Female Viagra is ineffective at improving sexual desire in women, so FDA doesn’t approve the medicine.
After much review and public controversy, the FDA met this week and determined that flibanserin, a new medication that was hoped to be an effective treatment for female sexual arousal disorder, did not significantly improve symptoms of the disorder, and ruled against approving the medication.
Female sexual arousal disorder, also known as hypoactive sexual desire disorder, (HSDD) is a relatively new diagnosis. It was historically known as frigidity, and more attention was given to the concept of the lack of sexual desire or arousal as a biological disorder potentially treatable with pharmaceuticals. When Sildenifil (Viagra) appeared on the market with enormous publicity and profit for the pharmaceutical industry, a lack of desire in women came under consideration as a potentially treatable disease.
HSDD is often defined by a persistent lack of desire or a lack of sexual fantasies. Women with HSDD rarely initiate sex or seek sexual satisfaction. It is thought that as many as 10 percent of American women may suffer from HSDD.
Possible causes may include stress, relationship problems, anger, or a lack of intimacy with sex partners. There are also known medical causes including side effects of certain medications including some antidepressants, blood pressure medications, and birth control pills. Menopause may also decrease sexual arousal and stimulation, as well as depression.
{ LiveScience | Continue reading }
The female-libido-boosting drug flibanserin proved marginally effective in two trials reported by the FDA on Wednesday. Still, its side effects may outweigh whatever benefits it offers: 15 percent of participants stopped taking the drug due to dizziness, nausea, anxiety, or insomnia. Why does it seem like every drug causes the same side effects?
